{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:30:34Z","timestamp":1793813434931,"version":"4.6.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2024-I2M-2-001-1"],"award-info":[{"award-number":["2024-I2M-2-001-1"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jhepr.2026.101997","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:15:43Z","timestamp":1787008543000},"page":"101997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic vaccination strategy targeting the PreS1 region of L-HBsAg for HBV\/HDV co-infection"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6517-6483","authenticated-orcid":false,"given":"Rebecca A.","family":"Russell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9719-4312","authenticated-orcid":false,"given":"James","family":"Lok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-3496","authenticated-orcid":false,"given":"James M.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senko","family":"Tsukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa M.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1198-6090","authenticated-orcid":false,"given":"Bethany G.","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4754-828X","authenticated-orcid":false,"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.C.","family":"Wing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumi","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane A.","family":"McKeating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1909-7095","authenticated-orcid":false,"given":"Matthew D.J.","family":"Dicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101997_bib1","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101997_bib2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0168-8278(01)00028-9","article-title":"Efficacy and limitations of a specific immunotherapy in chronic hepatitis B","volume":"34","author":"Pol","year":"2001","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101997_bib3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.coviro.2018.04.003","article-title":"Overcoming immune tolerance in chronic hepatitis B by therapeutic vaccination","volume":"30","author":"Dembek","year":"2018","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jhepr.2026.101997_bib4","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.3389\/fimmu.2019.02240","article-title":"Heterogeneity of HBV-specific CD8+ T-cell failure: implications for immunotherapy","volume":"10","author":"Heim","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2026.101997_bib5","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1097\/HEP.0000000000000431","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference","volume":"78","author":"Ghany","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101997_bib6","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"eLife"},{"key":"10.1016\/j.jhepr.2026.101997_bib7","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.gastro.2013.12.024","article-title":"Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes","volume":"146","author":"Ni","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101997_bib8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/0042-6822(89)90564-3","article-title":"Identification of an attachment site for human liver plasma membranes on hepatitis B virus particles","volume":"173","author":"Pontisso","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.jhepr.2026.101997_bib9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1053\/j.gastro.2005.03.090","article-title":"Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes","volume":"129","author":"Glebe","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101997_bib10","doi-asserted-by":"crossref","first-page":"9786","DOI":"10.1128\/JVI.79.15.9786-9798.2005","article-title":"Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition","volume":"79","author":"Barrera","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jhepr.2026.101997_bib11","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/hep.29239","article-title":"Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice","volume":"66","author":"Bian","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101997_bib12","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1136\/gutjnl-2017-313811","article-title":"Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers","volume":"67","author":"Pfefferkorn","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.101997_bib13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/hep.1840120204","article-title":"Fine specificity of human antibody response to the PreS1 domain of hepatitis B virus","volume":"12","author":"Alberti","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101997_bib14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3748\/wjg.v8.i2.276","article-title":"Detection of anti-preS1 antibodies for recovery of hepatitis B patients by immunoassay","volume":"8","author":"Wei","year":"2002","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101997_bib15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41565-020-0648-y","article-title":"Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B","volume":"15","author":"Wang","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.jhepr.2026.101997_bib16","doi-asserted-by":"crossref","first-page":"E690","DOI":"10.1073\/pnas.1115485109","article-title":"Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin","volume":"109","author":"Zakeri","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2026.101997_bib17","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.jhep.2018.08.012","article-title":"Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels","volume":"69","author":"Ko","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101997_bib18","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.26738","article-title":"A potent human neutralizing antibody Fc-dependently reduces established HBV infections","volume":"6","author":"Li","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.jhepr.2026.101997_bib19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/cei.13614","article-title":"Therapeutic vaccination for treatment of chronic hepatitis B","volume":"205","author":"Cargill","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jhepr.2026.101997_bib20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8+ T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.jhepr.2026.101997_bib21","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1056\/NEJMc2115596","article-title":"Differential kinetics of immune responses elicited by Covid-19 vaccines","volume":"385","author":"Collier","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101997_bib22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41541-021-00336-1","article-title":"Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2","volume":"6","author":"McDonald","year":"2021","journal-title":"NPJ Vaccin"},{"key":"10.1016\/j.jhepr.2026.101997_bib23","article-title":"HBV001: phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV","volume":"5","author":"Cargill","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.101997_bib24","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2024.06.027","article-title":"Phase Ib\/IIa randomized study of heterologous ChAdOx1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB","volume":"81","author":"Tak","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101997_bib25","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/vaccines8020184","article-title":"The design and development of a multi-HBV antigen encoded in chimpanzee adenoviral and modified vaccinia Ankara viral vectors; a novel therapeutic vaccine strategy against HBV","volume":"8","author":"Chinnakannan","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jhepr.2026.101997_bib26","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jhep.2022.12.013","article-title":"Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models","volume":"78","author":"Su","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101997_bib27","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Boni","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jhepr.2026.101997_bib28","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/gutjnl-2018-316641","article-title":"Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load","volume":"68","author":"Schuch","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.101997_bib29","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.chembiol.2021.07.005","article-title":"DogCatcher allows loop-friendly protein\u2013protein ligation","volume":"29","author":"Keeble","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.jhepr.2026.101997_bib30","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1016\/j.ymthe.2022.08.002","article-title":"Modular capsid decoration boosts adenovirus vaccine-induced humoral immunity against SARS-CoV-2","volume":"30","author":"Dicks","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.jhepr.2026.101997_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020977","article-title":"Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1","volume":"6","author":"Biswas","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2026.101997_bib32","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/sj.gt.3303104","article-title":"Identification of the immunodominant CTL epitope of EGFP in C57BL\/6 mice","volume":"15","author":"Han","year":"2008","journal-title":"Gene Ther"},{"key":"10.1016\/j.jhepr.2026.101997_bib33","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/eji.200324125","article-title":"Different immunogenicity of H-2 Kb-restricted epitopes in natural variants of the hepatitis B surface antigen","volume":"33","author":"Schirmbeck","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jhepr.2026.101997_bib34","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1136\/gutjnl-2014-308041","article-title":"TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice","volume":"64","author":"Martin","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.101997_bib35","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3390\/v13081503","article-title":"Rapid and robust continuous purification of high-titer hepatitis B virus for in vitro and in vivo applications","volume":"13","author":"Wettengel","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jhepr.2026.101997_bib36","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201900355","article-title":"A dual role for SAMHD1 in regulating HBV cccDNA and RT-dependent particle genesis","volume":"2","author":"Wing","year":"2019","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.jhepr.2026.101997_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104936","article-title":"Characterization of hepatitis B virus surface antigen particles expressed in stably transformed mammalian cell lines containing the large, middle and small surface protein","volume":"183","author":"Battagliotti","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhepr.2026.101997_bib38","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1038\/s41598-017-02460-2","article-title":"Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2026.101997_bib39","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","article-title":"Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease","volume":"70","author":"Urban","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.101997_bib40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jhep.2024.05.001","article-title":"Bulevirtide monotherapy in patients with chronic HDV: efficacy and safety results through week 96 from a phase III randomized trial","volume":"81","author":"Wedemeyer","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101997_bib41","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jhep.2024.01.035","article-title":"Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies","volume":"80","author":"Allweiss","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101997_bib42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus-like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jhepr.2026.101997_bib43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.chom.2025.12.001","article-title":"Functional immune responses induced by a capsid assembly modulator in chronic hepatitis B virus-infected humanized mice","volume":"34","author":"Fernandes","year":"2026","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jhepr.2026.101997_bib44","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.cgh.2023.02.032","article-title":"New perspectives on development of curative strategies for chronic hepatitis B","volume":"21","author":"Feld","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101997_bib45","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/j.gastro.2025.02.016","article-title":"The impact of hepatitis B surface antigen reduction via small interfering RNA treatment on natural and vaccine (BRII-179)-induced hepatitis B virus-specific humoral and cellular immune responses","volume":"169","author":"Ji","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101997_bib46","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0168-8278(24)00472-0","article-title":"OS-031 Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NA-suppressed CHB subjects than 24 weeks of imdusiran alone","volume":"80","author":"Agarwal","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101997_bib47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1056\/NEJMoa2508827","article-title":"A phase 2 trial of tobevibart plus elebsiran in hepatitis D","volume":"394","author":"Asselah","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101997_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(24)01178-4","article-title":"SAT-536 uptake and T cell stimulation by anti-HBs monoclonal antibody BJT-778-rHBsAg immune complexes","volume":"80","author":"Salimzadeh","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101997_bib49","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1056\/NEJMoa2314134","article-title":"Bulevirtide combined with pegylated interferon for chronic hepatitis D","volume":"391","author":"Asselah","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.101997_bib50","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0168-8278(25)00313-7","article-title":"LBO-004 Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis delta and 96 weeks of posttreatment follow-up","volume":"82","author":"Wedemeyer","year":"2025","journal-title":"J Hepatol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T16:40:20Z","timestamp":1793810420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926002685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2589555926002685"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101997","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic vaccination strategy targeting the PreS1 region of L-HBsAg for HBV\/HDV co-infection","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101997","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101997"}}